FDA Issues Warning Letter to Chemco Corporation for CGMP Equipment Violations

The FDA issued a warning letter to Chemco Corporation on January 15, 2025, citing significant current Good Manufacturing Practice (CGMP) violations related to equipment maintenance failures that resulted in adulterated drug products. Wholesale distributors sourcing from Chemco or conducting supplier qualification audits should review the cited deficiencies as compliance signals during vendor assessment.

Regulatory Context

The warning letter was issued under 21 CFR Part 211.67 (Equipment Cleaning and Maintenance) and 21 CFR Part 211.100 (Written Procedures; Deviations). The FDA conducted an inspection of Chemco's Clifton, New Jersey facility from September 18-29, 2024. The inspection identified systemic failures in equipment maintenance protocols that directly compromised the quality of finished drug products distributed into the U.S. market.

Under CGMP regulations, manufacturers must establish and follow written procedures for equipment maintenance, cleaning, and sanitization. Equipment must be maintained to prevent contamination or mix-ups that could affect product quality. The FDA's enforcement action indicates these procedures were either absent or not followed at Chemco's facility.

Key Violations Cited

The warning letter identifies three significant deficiencies:

Equipment maintenance failures (21 CFR 211.67): Chemco failed to maintain equipment used in the manufacture of injectable drug products. The FDA documented instances where critical filling equipment was not properly cleaned between production runs, creating risk of cross-contamination between different drug products. Inspection records showed gaps of up to 45 days between scheduled maintenance and actual equipment servicing.

Inadequate investigation procedures (21 CFR 211.192): When deviations were identified during batch production, Chemco did not conduct thorough investigations to determine root cause. The FDA cited 14 instances where deviations were closed without adequate justification or corrective action. One deviation involving a malfunctioning temperature probe was documented but not investigated for impact on product stability.

Lack of written procedures (21 CFR 211.100): Chemco did not establish written procedures for equipment cleaning validation. The FDA found that cleaning procedures existed but were not validated to demonstrate effective removal of drug residues and cleaning agents. This failure meant Chemco could not demonstrate that equipment was adequately cleaned between product runs.

The warning letter states that drug products manufactured under these conditions are considered adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

Response Required

Chemco must respond to the FDA within 15 working days of receipt, stating specific steps taken to correct the violations. The FDA requested:

• A comprehensive retrospective assessment of all batches manufactured using the deficient equipment
• Corrective and preventive action (CAPA) plan with completion timelines
• Commitment to hire a qualified third-party consultant to conduct a facility-wide CGMP assessment

Until the FDA confirms adequate corrective action, Chemco's drug applications and supplements may be placed on hold. New drug applications referencing Chemco as a manufacturing site will not be approved.

Implications for Wholesale Distributors

This warning letter creates immediate compliance considerations for wholesale drug distributors conducting supplier qualification. Under DSCSA requirements, wholesale distributors must only conduct transactions with authorized trading partners. While a warning letter does not revoke a manufacturer's registration, it represents a documented compliance deficiency that should be factored into risk-based supplier assessments.

Distributors sourcing products manufactured by Chemco should review current inventory for batch codes produced during the inspection period (September 2024). Quality agreements with Chemco should require notification of regulatory actions. Distributors maintaining FDA warning letter databases as part of their supplier qualification program should add this citation to their monitoring protocols.

The equipment maintenance failures cited here—particularly the cross-contamination risks and inadequate deviation investigations—are red flags during facility audits. Distributors conducting on-site supplier audits should verify that manufacturers maintain validated cleaning procedures and complete scheduled equipment maintenance on time.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 73 have at least one FDA enforcement action on record—including warning letters, recalls, or import alerts. This warning letter to Chemco Corporation reinforces why wholesale distributors must monitor manufacturer compliance signals as part of supplier qualification workflows.

The average compliance score in the ColdChainCheck directory is 51/100, placing most entities in the "Fair" tier (919 of 1,275 entities). While ColdChainCheck scores focus on distributor compliance posture—state licensure, NABP accreditation, FDA registration—the underlying methodology accounts for enforcement actions as negative compliance signals. A manufacturer warning letter does not directly affect a distributor's score, but distributors sourcing from manufacturers with active FDA enforcement actions face elevated audit risk.

Practical Steps for QA and Compliance Teams

• Check your supplier list against the FDA warning letter database. Cross-reference current manufacturing partners with FDA's publicly available enforcement data. If Chemco Corporation appears on your approved supplier list, review quality agreements to determine if the New Jersey facility produces any products in your current inventory.

• Use the ColdChainCheck directory to verify distributor compliance posture. If you source products indirectly through a wholesale distributor rather than directly from the manufacturer, confirm the distributor holds active state licenses and FDA registration. Entities with compliance scores below 40 may lack complete licensure coverage or have enforcement actions on record.

• Update supplier qualification procedures to include equipment maintenance verification. During on-site audits or document reviews, request evidence of validated cleaning procedures (per 21 CFR 211.67) and maintenance logs showing adherence to scheduled servicing. Manufacturers unable to provide this documentation present similar risk to the deficiencies cited in Chemco's warning letter.

• Monitor ongoing FDA enforcement. ColdChainCheck tracks FDA warning letters as part of its compliance scoring methodology. Wholesale distributors can reference the DSCSA compliance checklist for coverage of trading partner verification requirements and authorized trading partner protocols.

This warning letter is publicly available in the FDA's enforcement database. ColdChainCheck enriches entity profiles by cross-referencing FDA enforcement data with state licensure records, enabling compliance teams to spot red flags during vendor qualification without manually checking multiple agency databases.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale distributors should verify compliance requirements with legal counsel and the relevant regulatory authorities.